Pharmaceutical firm Vascarta announced on Monday that Dr. Janet Loesberg has joined the Summit-based firm as fractional chief strategy officer. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, chairman, CEO and president.
Loesberg brings a wealth of pharmaceutical and leadership expertise to Vascarta. She has served in executive global medical affairs and R&D roles at Blueprint Medicines, Janssen Pharmaceuticals (div. of Johnson & Johnson), Bristol-Myers Squibb, and Pfizer. She was a board member at Ambrx, a clinical stage biotech company.
Most recently, as senior vice president of Blueprint Medicines, she was responsible for the medical strategy behind the successful launch of Ayvakit™ (avapritinib) for indolent systemic mastocytosis, a rare hematologic disorder. Her experience with the hematologic community will greatly benefit Vascarta as it develops Vasceptor® (VAS-101) for sickle cell disease.
“We are thrilled to welcome Janet to Vascarta and look forward to leveraging her deep industry expertise and business transformation experience as we focus on developing Vasceptor® for sickle cell disease and osteoarthritis,” Prince said. “Janet is a world-class executive with a proven track record in developing and commercializing medicines and we expect her to contribute greatly to moving our company into the future.”
